Shanghai Medicilon Inc.

  The continuous flow chemistry technology service platform is one of the important technologies used by Medicilon to support green chemistry. Based on the specific reactions of the innovative drug synthesis process, we can conduct feasibility assessment of continuous reactions, process development and optimization, and continuous improvement of the process to improve the research and development efficiency of the synthesis process and reduce the development cost of innovative drugs. Continuous flow chemistry refers to chemical reactions taking place in a continuously flowing fluid.  Raw materials and reagents are formulated into solutions and pumped into the reaction channels from different containers, where chemical transformations subsequently occur.  Commonly used reactors in continuous flow chemistry are microreactors and medium-sized reactors. Microreactors usually refer to reactors with a three-dimensional structure, whose internal dimensions are less than 1 mm and range from 1

STAT3 , a member of the STAT family, is a latent transcription factor that is activated in response to various cytokines, growth factors, and oncogene signals. STAT3 is constitutively activated in various human cancers, and its activation is frequently associated with poor prognosis. As a transcription factor, STAT3 regulates a set of genes implicated in cancer cell survival, proliferation, angiogenesis, invasion, metastasis, drug resistance, and immune evasion. Medicilon provides STAT3 drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, safety evaluation and other services. Introduction of STAT3 The signal transducer and activator of transcription (STAT) is a family of intracellular cytoplasmic transcription factors involved in many biological functions in mammalian signal transduction. Among them, STAT3 is involved in cell proliferation, differentiation, apoptosis, and inflammatory responses, and also STAT3-related signaling pathways are aberrant ov

  RAS is one of the most frequently mutated oncogenes in human cancer. KRAS is the isoform most frequently mutated, which constitutes about 85% of RAS mutations. As the most frequently mutated RAS isoform, KRAS is intensively studied in the past years. In the formulation of KRAS integrated research plan, Medicilon has in-depth communication with customers. The backbone of scientific research has combined the characteristics of each case with years of practical experience and technical accumulation, and carefully submitted high-quality experimental plans and results to customers. Medicilon provides KRAS-targeted drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, safety evaluation and other services. Targeting the untargetable KRAS [1] Introduction of KRAS RAS is a family of GTPase proto-oncogenes, comprising three closely related RAS isoforms: HRAS, KRAS and NRAS. From all of the RAS isoforms, KRAS is most frequently mutated, followed by NRAS and the